On Mar. 17, 2020, Regeneron announced that its scientists had isolated hundreds of virus-neutralizing, fully human antibodies from the company’s VelocImmune mice, which have been genetically-modified to have a human immune system.

Regeneron

also isolated antibodies from humans who have recovered from COVID-19, in order to maximize the pool of potentially potent antibodies. Regeneron previously developed a successful treatment for Ebola virus infection, which is currently under review by the U.S. Food and Drug Administration.